Literature DB >> 29318396

New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.

Hiroshi Nishioka1,2, Naoko Inoshita3,4.   

Abstract

WHO classification of pituitary adenomas was revised in 2017. The two major and significant changes are discussed. (1) The new classification focuses on adenohypophysial-cell lineage for the designation of adenomas, and thus, assessment of pituitary transcription factors is recommended. Its appropriate use has a complementary role in obtaining an accurate diagnosis, particularly in hormone-negative adenomas. Subclassification of nonfunctioning adenomas was revised accordingly and, consequently, null cell adenomas became quite rare. (2) "Atypical adenoma", a previous category, was eliminated due to the poor reproducibility and predictive value. Assessment of tumor proliferation marker and other clinical parameters such as invasion are recommended to predict aggressiveness. "High-risk adenomas" are those with rapid growth, radiological invasion, and a high Ki-67 proliferation index, whereas some special adenoma subtypes commonly show aggressive behavior.

Entities:  

Keywords:  Aggressive adenomas; Nonfunctioning adenomas; Pituitary adenomas; Transcription factor; WHO classification

Mesh:

Substances:

Year:  2018        PMID: 29318396     DOI: 10.1007/s10014-017-0307-7

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  22 in total

1.  Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers.

Authors:  Joao Paulo Almeida; Corbin C Stephens; Jennifer M Eschbacher; Michelle M Felicella; Kevin C J Yuen; William L White; Michael A Mooney; Anne Laure Bernat; Ozgur Mete; Gelareh Zadeh; Fred Gentili; Andrew S Little
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

2.  Predicting pituitary adenoma consistency with preoperative magnetic resonance elastography.

Authors:  Salomon Cohen-Cohen; Ahmed Helal; Ziying Yin; Matthew K Ball; Richard L Ehman; Jamie J Van Gompel; John Huston
Journal:  J Neurosurg       Date:  2021-10-29       Impact factor: 5.408

3.  Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.

Authors:  John P Andrews; Rushikesh S Joshi; Matheus P Pereira; Taemin Oh; Alexander F Haddad; Kaitlyn M Pereira; Robert C Osorio; Kevin C Donohue; Zain Peeran; Sweta Sudhir; Saket Jain; Angad Beniwal; Ashley S Chopra; Narpal S Sandhu; Tarik Tihan; Lewis Blevins; Manish K Aghi
Journal:  World Neurosurg       Date:  2021-04-20       Impact factor: 2.210

4.  Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue.

Authors:  Raitis Peculis; Ilona Mandrika; Ramona Petrovska; Rasma Dortane; Kaspars Megnis; Jurijs Nazarovs; Inga Balcere; Janis Stukens; Ilze Konrade; Valdis Pirags; Janis Klovins; Vita Rovite
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-22       Impact factor: 5.555

5.  MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.

Authors:  Shinsuke Uraki; Hiroyuki Ariyasu; Asako Doi; Ken Takeshima; Shuhei Morita; Hidefumi Inaba; Hiroto Furuta; Noriaki Fukuhara; Naoko Inoshita; Hiroshi Nishioka; Naoyuki Nakao; Shozo Yamada; Takashi Akamizu
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923

6.  Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors.

Authors:  Keiko Taniguchi-Ponciano; Sergio Andonegui-Elguera; Eduardo Peña-Martínez; Gloria Silva-Román; Sandra Vela-Patiño; Erick Gomez-Apo; Laura Chavez-Macias; Guadalupe Vargas-Ortega; Laura Espinosa-de-Los-Monteros; Baldomero Gonzalez-Virla; Carolina Perez; Aldo Ferreira-Hermosillo; Etual Espinosa-Cardenas; Claudia Ramirez-Renteria; Ernesto Sosa; Blas Lopez-Felix; Gerardo Guinto; Daniel Marrero-Rodríguez; Moises Mercado
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

7.  Metabolic Reprogramming Drives Pituitary Tumor Growth through Epigenetic Regulation of TERT.

Authors:  Hiromi Onizuka; Kenta Masui; Kosaku Amano; Takakazu Kawamata; Tomoko Yamamoto; Yoji Nagashima; Noriyuki Shibata
Journal:  Acta Histochem Cytochem       Date:  2021-06-23       Impact factor: 1.938

8.  The Past, Present, and Future Statuses of Formerly Classified "Atypical Pituitary Adenomas": A Clinicopathological Assessment of 101 Cases in a Cohort of More than 1,000 Pure Endoscopically Treated Patients in Single Center.

Authors:  Ercan Bal; İbrahim Kulaç; Selim Ayhan; Figen Söylemezoğlu; Mustafa Berker
Journal:  J Neurol Surg B Skull Base       Date:  2020-02-20

9.  Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.

Authors:  Paraskevi Xekouki; Emily J Lodge; Jakob Matschke; Alice Santambrogio; John R Apps; Ariane Sharif; Thomas S Jacques; Simon Aylwin; Vincent Prevot; Ran Li; Jörg Flitsch; Stefan R Bornstein; Marily Theodoropoulou; Cynthia L Andoniadou
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

10.  Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.

Authors:  Beata Rak; Maria Maksymowicz; Monika Pękul; Grzegorz Zieliński
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-31       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.